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The article by Conte et al.1 on behalf of the Society for Vascular Surgery (SVS) in this issue of the Journal of Vascular
Surgery provides guidelines for improving the consistency and interpretability of clinical trials intended to evaluate
treatment options for patients with critical limb ischemia (CLI). This article identifies a number of key challenges with
conducting and comparing CLI trials, including the wide spectrum of clinical presentations that CLI encompasses, the
use of disparate eligibility criteria and endpoint measurements, and logistical and economic considerations that can limit
study initiation and completion. The authors propose definitions for a number of performance goals derived from
historical surgical literature as a means of reducing the negative impact of these factors. The current editorial reviews
aspects of this proposal from the perspective of the authors in terms of their understanding of the statutory obligations
of the U.S. Food and Drug Administration (FDA) to regulate the marketing of cardiovascular devices based on valid
scientific evidence. (J Vasc Surg 2009;50:1474-6.)REGULATORY BACKGROUND
Since the passage of the Medical Device Amendments
to the Food, Drug, and Cosmetic Act in 1976, FDA has
been charged with regulating marketing approval of new
medical devices.2 Permission to market a new device is
based on a review of valid scientific evidence that provides
reasonable assurance that the device is both safe and effec-
tive for use in an intended population for a specified indi-
cation, based on a determination that the probable benefits
of device use outweigh the probable risks. This aspect of
FDA’s mission is limited to regulating medical device and
their manufacturers; the Agency is explicitly prevented
from any such regulation of practitioners or the practice of
medicine by the FDA Modernization Act of 1997.3 Thus,
physicians may use any currently marketed device in a
manner they deem would be in the best interests of their
patient. Such “off-label use” often occurs with the inter-
ventional treatment of peripheral vascular atherosclerotic
disease, in that these devices are frequently used outside of
their approved indications. One consequence of this prac-
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1474tice is the reduced incentive for manufacturers to conduct
pivotal clinical trials to support FDA approval for these
indications if their devices are already marketed for other
intended uses. It is also important to note that FDA does
not regulate or approve types of medical procedures by
themselves, only the devices used therein, and that labeled
indications are limited to those allowed by FDA based on
submitted information.
REGULATORY REQUIREMENTS FOR
DEVICE EVALUATION
There are three main pathways for medical devices to
enter the market: Premarket Notification via demonstra-
tion of substantial equivalence to a similar marketed device
(commonly known as 510[k], the section of the Medical
Device Amendments that defines this program); approval
of a Premarket Approval Application (PMA), which re-
quires demonstration of safety and effectiveness for the
stated intended use; and approval of a Humanitarian De-
vice Exemption (HDE), which is based on demonstration
of safety and probable benefit in lieu of effectiveness for
devices intended to treat or diagnose a disease or condition
that affects fewer than 4,000 patients annually. Most per-
manent implants used to treat peripheral vascular athero-
sclerotic disease, including vascular stents and endovascular
grafts for treating aortic aneurysms, are regulated via the
PMA pathway because they present the highest level of risk
to the patient in event of failure, and because FDA believes
that a complete set of special controls such as performance
standards does not yet exist for allowing these devices to be
cleared via 510(k). By contrast, many non-implant devices
such as peripheral balloon angioplasty catheters and
atherectomy devices reach the marketplace via the 510(k)
pathway through a determination of substantial equiva-
lence, due to the lower risk profile that these devices
present.
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tial equivalence or reasonable assurance of safety and effec-
tiveness frequently involves the collection of clinical data to
support the proposed intended use. FDA typically recom-
mends that such data be collected through the conduct of
randomized, controlled trials (RCTs), as such studies pro-
vide the highest levels of clinical evidence and patient
comparability.4 However, in accordance with the “least
burdensome” provisions specified in the FDA Moderniza-
tion Act of 1997,5 FDA accepts data from alternative study
designs, such as single-arm studies using historical controls,
provided the data are scientifically sound and free of bias.
Such studies have been used to support marketing clearance/
approval when an RCT is not possible due to ethical
concerns or challenges in achieving a satisfactory rate of
subject enrollment. Acceptance of clinical data resulting
from non-RCTs is facilitated when objective performance
criteria (OPCs) have been developed, as they have for
certain cardiovascular devices such as prosthetic surgical
heart valves and ventricular assist devices. Development of
robust OPCs generally requires relatively mature device
technology and the availability of high-quality historical
clinical evidence.
The Society for Vascular Surgery (SVS) authors pro-
pose a similar approach for evaluating new devices used in
the treatment of critical limb ischemia (CLI). As part of this
approach, SVS reviewed the available literature to identify
suitable reports of RCTs involving endovascular, pharma-
cologic, and surgical treatments, and formulated sets of
standardized endpoint definitions, entry criteria, and per-
formance benchmarks for use in designing CLI studies.
Because these historical studies vary greatly in their designs
and definitions, the authors elected to define these stan-
dards as “objective performance goals,” rather than OPCs.
Development of proper OPCs may be possible once addi-
tional, standardized clinical data from CLI studies are avail-
able.
In addition to their goal of enhancing comparability
across different CLI studies, the SVS authors also believe
that single-arm studies designed using their proposed def-
initions and metrics can facilitate the timely evaluation and
adoption of new treatment options for CLI. From a regu-
latory standpoint, such an approach can provide a “least
burdensome” pathway for device approval/clearance, pro-
vided the data collected are sufficiently robust and applica-
ble to the relevant CLI population. Single-arm studies and
other alternative study designs have been successfully used
to support marketing submissions for other peripheral vas-
cular devices, thus allowing physicians access to additional
novel treatment options.
THE SVS PROPOSAL FOR CRITICAL LIMB
ISCHEMIA TRIALS
SVS has conducted a laudable effort to facilitate the
clinical investigation of devices for treating patients with
CLI, a population sorely lacking evidence-based treatment
strategies. The Society’s research has identified useful pa-
rameters for designing new CLI studies, and culled outsome of the challenges with leveraging historical data for
use as a control for comparing diverse treatment options.
The following are our comments on the SVS proposal with
respect to the evaluation and subsequent approval/clearance
of devices used to treat CLI, as part of our efforts to provide
a transparent and least burdensome regulatory review pro-
cess.
In their analysis, the SVS authors have analyzed and
compiled the best available literature to provide a historical
baseline for the evaluation of devices to treat CLI. They
identified three trials with available patient-level data from
control patients who underwent surgical bypass, the cur-
rent gold standard for revascularization. Based on their
goals for management of CLI patients, they formulated
eight metrics of import to the assessment of revasculariza-
tion in CLI, encompassing clinical as well as functional
endpoints. Each provides an important assessment and can
provide baseline data for comparison when evaluating
novel devices.
CLI as a disease entity is heterogeneous, with a final
common pathway of limb ischemia and tissue loss. The
underlying pathology, comorbidities, patient demograph-
ics, and vascular anatomy vary among patients. Treatment
goals vary across patients, and strategies for successful treat-
ment are necessarily different depending on the individual
patient scenarios and the techniques and devices used. As
such, treatment of CLI often entails a multi-factorial treat-
ment strategy, using multiple modalities at multiple ana-
tomic levels. The treating physician thus needs an arma-
mentarium of devices and procedures, and often employs
several in an individual patient. From a regulatory stand-
point, each “tool” in this “toolbox” must be shown to be
safe and effective for its intended use prior to marketing
clearance or approval.
Designing trials to evaluate each device poses chal-
lenges to standardization, as each fits a unique niche within
the overall treatment paradigm. Devices may be indicated
for specific instances, and in particular patient populations.
As a result, each device may have its own set of relevant
outcome metrics and significant adverse event types.6
This heterogeneity in patient demographics and treat-
ment effects means that different devices may be best
assessed using different metrics and endpoints. The use of
historical controls in such a situation becomes challenging
due to differences in clinical cohorts and in the action of the
devices themselves.4 While there is some published data
regarding treatment of patients with CLI, most of the data
that exist are specific to the devices or procedures studied.
The SVS analysis can be seen as providing a starting
point for designing prospective clinical studies involving
CLI treatment. With this approach, sponsors can cull out
historical outcomes for patients with characteristics that
match the population to be treated to derive appropriate
performance goals. Specifically, in addition to overall pa-
tient demographics and comorbidities, SVS has identified
octogenarian status and the presence of tissue loss as being
characteristic of a “Clinical High Risk” patient subgroup
predictive of worse outcomes.1 The performance goals are
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with these high-risk features, and the portability of the
performance goals to subsequent trial designs is therefore
predicated on proper matching of study cohorts.
It is expected that different combinations of the eight
identified metrics may be appropriate for comparisons of
individual devices, based on the particular technology and
patient population studied. In addition, we expect that
functional, as well as clinical and anatomic, endpoints may
be appropriate for the assessment of new device-based
treatment options.
This ground breaking work by SVS can be used as the
basis for clinical evaluation of the first generation of endo-
vascular devices to treat CLI. We hope that as additional
CLI studies are completed and the body of available clinical
evidence becomes larger, the performance goals can be
updated and further refined to reflect more recent stan-
dards of care, thus forming a clinical database for future
treatment comparisons. In particular, we expect that, over
time, robust data from endovascular approaches will be
available, from which performance goals can be generated
for use in evaluating the next generation of devices. Future
study designs can incorporate these baseline data sets and
facilitate the most suitable comparisons of subject devices
based on their technological characteristics and indicated
patient population.
It is important to note that certain limitations are
inherent in the design of any single-arm study. The pres-
ence of confounding factors, such as patient demographics,
anatomy, differences in comorbidities and the extent of
disease, and the proportion of clinical high-risk features,
can result in treatment and control groups that are not
completely comparable, thus diminishing the interpretabil-
ity of the resulting data.4 While the impact of known
confounders can potentially be addressed through statisti-
cal techniques, unknown confounding factors may always
be present and their effects cannot easily be quantified. In
addition, certain novel device types, such as drug-device
combination products, may not be suitable for evaluation
in a single-arm study because historical data may not rep-
resent an adequate comparator due to differences in tech-
nology and clinical practice. RCTs may be necessary to
evaluate these types of products.
CONCLUSION
Clinical trial designs always incorporate a delicate bal-
ancing act. Study sponsors must carefully define the appro-
priate target population and outcome measures, weigh the
risks of the procedure versus the potential benefits, estab-
lish clinically meaningful goals for study success and design
a study that can reasonably be completed in a timely fash-
ion. Because the possible treatment options for CLI are
diverse, much like the manifestations of the disease itself, asingle paradigm for CLI study design may not be sufficient
to evaluate all device types or patient populations in the
most appropriate manner. Enhancing the design of clinical
studies is an area that can be facilitated greatly through the
collaboration of all stakeholders interested in learning how
to better treat patients, including the clinical community,
medical device manufacturers, and regulatory agencies.
FDA believes that the definitions and performance
goals developed by SVS may help to define a starting point
for industry sponsors considering their own CLI studies.
We expect that modifications could be warranted, based on
the specific devices and populations to be studied. These
goals may aid the development of clinical trial designs
capable of evaluating the safety and effectiveness of periph-
eral vascular devices used to treat CLI, keeping in mind the
regulatory framework involved in these studies and the
specific scientific considerations outlined above. We sup-
port the continued conduct and refinement of CLI studies,
and would encourage interested study sponsors to discuss
potential study designs with FDA in the early planning
stages.
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